Experimental Models of Epilepsy and Related Comorbidities, Volume II

38.1K
views
39
authors
7
articles
Editors
4
Impact
Loading...
3,440 views
14 citations
Mini Review
06 October 2022
Epilepsy treatment in neuro-oncology: A rationale for drug choice in common clinical scenarios
José Manuel Sánchez-Villalobos
3 more and 
Miguel Alcaraz

Epilepsy represents a challenge in the management of patients with brain tumors. Epileptic seizures are one of the most frequent comorbidities in neuro-oncology and may be the debut symptom of a brain tumor or a complication during its evolution. Epileptogenic mechanisms of brain tumors are not yet fully elucidated, although new factors related to the underlying pathophysiological process with possible treatment implications have been described. In recent years, the development of new anti-seizure medications (ASM), with better pharmacokinetic profiles and fewer side effects, has become a paradigm shift in many clinical scenarios in neuro-oncology, being able, for instance, to adapt epilepsy treatment to specific features of each patient. This is crucial in several situations, such as patients with cognitive/psychiatric comorbidity, pregnancy, or advanced age, among others. In this narrative review, we provide a rationale for decision-making in ASM choice for neuro-oncologic patients, highlighting the strengths and weaknesses of each drug. In addition, according to current literature evidence, we try to answer some of the most frequent questions that arise in daily clinical practice in patients with epilepsy related to brain tumors, such as, which patients are the best candidates for ASM and when to start it, what is the best treatment option for each patient, and what are the major pitfalls to be aware of during follow-up.

11,992 views
12 citations
Systematic Review
15 September 2022

Purpose: To explore the effectiveness of different anti-seizure medications in preventing early and late post-traumatic epilepsy (PTE). The efficacy, treatment-related side-effects, and mortality of the different treatments were compared using a ranking model to identify the optimal treatment.

Methods: A comprehensive literature search was performed using Pubmed, Medline, Embase, and Cochrane library databases. All relevant published articles up to 10 March 2022 were evaluated. The quality of the extracted data was assessed using either the Cochrane risk of bias tool or the Newcastle-Ottawa scale. The primary outcome measures were early or late post-traumatic seizures. The secondary outcome measures were mortality, treatment-related adverse effects, length of hospital stay, and length of stay within the intensive care unit (ICU).

Results: A total of seven randomized controlled trials and 18 non-randomized controlled trials were included in this network meta-analysis. The trials included six interventions: Phenytoin (PHT)+phenobarbital (PB), levetiracetam (LEV), PHT, PHT-LEV, lacosamide (LCM), and valproate (VPA). All interventions except VPA significantly reduced the rate of early PTE in TBI patients compared with the placebo. Seven studies reported the impact of four treatments (PHT + PB, LEV, PHT, VPA) on late seizures and showed a significant reduction in the incidence of late seizures in patients with TBI compared with placebo. The impact of PHT, LEV, and VPA on mortality was reported in nine studies. PHT had no impact on mortality, but patients treated with both LEV and VPA had higher mortality than those treated with placebo. The treatment-related adverse effects of LEV, PHT, and LCM were reported in five studies. LEV and PHT had higher treatment-related adverse effects incidence than placebo, while LCM had no effect on treatment related-adverse effects.

Conclusion: LEV and PHT prevented early and late PTE. PHT also reduced the mortality rate in patients with TBI. Both LEV and PHT had higher treatment-related adverse effects compared with placebo. However, LEV had a slightly lower incidence of treatment-related adverse effects when compared with PHT. Compared with PHT, LEV did not reduce the length of hospital stay but shortened the length of ICU stays. Therefore, based on the findings of this meta-analysis, we speculate that LEV is the best treatment option for TBI patients. However, further high-quality randomized controlled trials are required to confirm these findings.

6,720 views
15 citations
Open for submission
Frontiers Logo

Frontiers in Pharmacology

The Interplay Between GABA and Glutamate in Systems Physiology and Pathophysiology
Edited by Jinwei Zhang, Stephen Lewis, Claudio Rivera
Deadline
05 September 2025
Submit a paper
Recommended Research Topics
Frontiers Logo

Frontiers in Neurology

Burden of Illness in People with Epilepsy: From Population-Based Studies to Precision Medicine
Edited by Adam Strzelczyk, Karl Martin Klein, Felix Von Podewils
81.6K
views
97
authors
14
articles
Frontiers Logo

Frontiers in Pharmacology

Experimental Models of Epilepsy and Related Comorbidities, Volume I
Edited by Mohd Farooq Shaikh, Annamaria Vezzani, Jafri Malin Abdullah, Ayanabha Chakraborti
94.1K
views
95
authors
13
articles
Frontiers Logo

Frontiers in Pharmacology

Experimental & Clinical Epilepsy and Related Comorbidities
Edited by Mohd Farooq Shaikh, Teresa Ravizza, Jafri Malin Abdullah, Ayanabha Chakraborti, Terence John O'Brien
56.2K
views
73
authors
11
articles
Frontiers Logo

Frontiers in Pharmacology

Classical and Modern Biotechnology Applied to the Treatment of Epilepsy and Anxiety Disorders
Edited by Renê Oliveira Beleboni, Norberto Cysne Coimbra, Márcia Renata Mortari, Liana Melo-Thomas
41.2K
views
27
authors
5
articles
Frontiers Logo

Frontiers in Neuroscience

Complementary/Alternative Therapies for Epilepsy and Related Psychiatric Comorbidities
Edited by Zhenghao Xu, Aubin Moutal, Yi Wang
77.4K
views
46
authors
7
articles